Disc Medicine, Inc
This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.
Inclusion Criteria for Participants with MF and Anemia: Participants are eligible for the study if all of the following criteria apply: 1. Age 18 years or older at the time of signing the informed consent form (ICF). 2. For Phase 1b: Dynamic International Prognostic Scoring System (DIPSS) score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to World Health Organization (WHO) 2016 criteria. For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate…
DISC-0974 is administered subcutaneously.